ASTS surged +12.42% to $62.73 during Wednesday's regular session, up from a prior close of $55.80. The rally was driven by Berenberg initiating coverage with a Buy rating and a $92 price target, implying roughly +65% upside.

VIOT shares surged roughly +85.57% during Tuesday's regular session, jumping from a $0.9693 prior close to about $1.80 on massive volume. The rally follows renewed focus on overseas momentum: North American Amazon business posted triple-digit H1 growth, with the flagship V6 Pro ranking top-8 in its category during Prime Day.

PLTR fell roughly -6% during Wednesday's regular session, sliding from a prior close of $179.92 to about $169. The primary catalyst was Google DeepMind's launch of Gemini 3.8 Flash Cyber and its "Fairwind" program, a direct push into Palantir's core government/defense AI market.

The selected price target is $10 per share , roughly a 110% gain from recent trading near $4.73 and below the stock's 52-week high of $12.99. Wall Street is notably bullish: the consensus analyst price target is $16 , with individual targets ranging from $13 to $20.

NTHI is up +5.92% during regular-session trading, climbing to roughly $5.01 from a $4.73 prior close. The gain follows a -4.25% pullback on Sept 1, reflecting sustained high volatility in this micro-cap clinical-stage biotech.

GPRO is up +39.02% today, trading near $1.71 during the regular session, extending a multi-day surge that has more than doubled shares off last week's ~$0.60 low. Primary driver: continued reaction to the definitive merger with private photonics firm Starman Optical, a pivot into AI data-center optics and defense that repays ~$92M of debt and pays shareholders $1.14/share plus a ~10% stake in the combined company.

BIAF is up +63.73% intraday to about $10.79, extending the prior session's +44.52% surge; the move occurred during regular market hours. Primary catalyst: the company announced plans to expand its CyPath Lung test into post-treatment surveillance of lung cancer survivors, broadening its commercial use beyond initial screening.

CRDO dropped about -18.65% in regular trading, sliding from a $206.63 prior close to roughly $168. The move extends a post-earnings selloff after fiscal Q1 results (revenue $479M, +115% YoY; EPS $1.20) beat estimates but GAAP gross margin fell to 64.5%, with Q2 guidance seen as thinner than prior quarters.

HTZ traded up +6.7% to about $2.39 during regular market hours versus the prior session's $2.24 close. The primary catalyst was a newly announced partnership with Uber to operate autonomous robotaxis and human-driven fleet operations.

Alphabet (GOOG) shares have declined roughly 10.7% over the past 30 days, slipping from a closing level near $372.47 to about $332.76 as of early September trading. The pullback reflects growing investor unease about AI capital spending, a historic turn to negative free cash flow, and the delayed rollout of the flagship Gemini 3.5 Pro model.

The $100 price target represents roughly a 139% gain from IREN's recent trading level near $42, and would require a breakout well above its prior 52-week high of $76.87. Strongest bullish factors: a landmark $9.7 billion AI cloud agreement with Microsoft and a large, largely owned power portfolio positioned for high-performance computing demand.

GTLB is up +14.62% intraday, trading near $51.68 versus a prior close of $45.09, with the move occurring during regular session trading. Primary catalyst: a strong Q2 FY2027 report, with revenue up roughly +21% year-over-year to ~$286M, beating estimates, alongside raised full-year revenue guidance.

DELL is up roughly +12.5% in Wednesday's session, trading near $478 versus Tuesday's $425.00 close, following a post-earnings surge that began after-hours and extended through premarket. The move was driven by a blowout fiscal Q2 2027 report: revenue rose +58% to about $47 billion and adjusted EPS of $7.04 crushed the ~$4.92 consensus.

PANW is down -8.48% to roughly $331.37 during regular trading, extending a post-earnings slide from Tuesday's $362.09 close. The move reflects a "beat-and-sell" reaction to Q4 FY26 results (released after Sept. 1 close), which beat revenue ($3.41B) and EPS ($1.02) but failed to satisfy lofty expectations.

FCEL dropped -10.71% to $15.25 from its prior close of $17.08, with the decline extending during regular trading. Primary catalyst: a wider-than-expected quarterly loss and a revenue miss reported before the open.

Purple Biotech (PPBT) has climbed roughly 73% over the trailing 30 days, from about $1.47 in early August to around $2.55. A U.S. patent Notice of Allowance covering tri-specific antibody designs from its CAPTN-3 platform was the primary catalyst, triggering unusually heavy trading volume.

Linkhome Holdings (LHAI) climbed roughly 44% over the last 30 days, rebounding from about $0.85 in early August to around $1.22 in early September. The advance follows a sharp late-June slide to near $0.65 and reflects renewed speculative interest in the company's pivot into AI infrastructure and GPU computing.

CRDO is down -10.45% to roughly $185 in Wednesday's session, extending an after-hours/overnight slide triggered by its fiscal Q1 report. The selloff came despite a beat: adjusted EPS of $1.20 vs. $1.17 expected and revenue up +115% YoY to $479M, above estimates.

MDB is trading down roughly -11.2% at about $385.60, versus a prior-session close of $434.21, extending an after-hours and premarket selloff into Wednesday's regular session. The move follows fiscal Q2 FY2027 results reported after Tuesday's close: revenue rose +30% to $771.8M and adjusted EPS of $1.90, both topping consensus.

The widely cited 12-month analyst price target for PPBT is $17 , implying a roughly tenfold move from recent prices in the $1.50–$2.30 range. The bullish case rests on the CAPTN-3 tri-specific antibody platform and lead candidate IM1240, which is advancing toward a first-in-human Phase 1 trial.